U C B SA (UCB.BR)
|Market Cap (Mil.):||€9,532.71|
|Shares Outstanding (Mil.):||183.43|
Shares in UCB rise 1.6 percent, among the top gainers on the pan-European FTSEurofirst 300 index, with traders citing speculation in German business daily Handelsblatt that the Belgian pharmaceutical group could be an attractive takeover target.
California looks to contain UC Santa Barbara big man Alan Williams on Friday when the Golden Bears visit the Gauchos, who have lost three of their last four. The 6-7 Williams leads the Gauchos in points (27.5) and rebounds (10.8), and the junior center has scored 62 points over the last two games, including 23 in Tuesday’s 13-point loss at UCLA. The Golden Bears snapped a two-game losing skid on Sunday with a 73-56 win over UC Irvine, and forward David Kravish has averaged 16.3 points and 10 reb
(Updated: CHANGES time of Brown 3-pointers to 103 seconds in Para 4)
Two under-the-radar West Coast basketball programs with NCAA Tournament potential square off Thursday night when UC Santa Barbara takes on host Colorado. Although neither team is currently ranked in the top 25, both have shown the potential to get there with impressive starts. UCSB, picked to finish second in the underrated Big West Conference, holds a 5-3 series edge, but the two teams have not played since 1996 when the Buffaloes scored a 76-55 home win.
BRUSSELS - Belgian pharmaceutical group UCB said on Friday that European regulators have recommended approval of its Cimzia drug for treating psoriatic arthritis in adults.
* Keeps 2013 forecast of 3.4 bln revenue, 680-710 mln EBITDA
BRUSSELS, Oct 25 - Belgian pharmaceutical company UCB confirmed its full-year guidance on Friday after growth of its three new medicines almost made up for declining sales of its former blockbuster epilepsy treatment in the first nine months.
BRUSSELS, July 31 - Belgian pharmaceutical group UCB reported first half core profit below expectations due to lower-than-expected sales of epilepsy drug Vimpat and higher research expenses.
BRUSSELS - Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favor of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis.
- A panel of advisers to the U.S. Food and Drug Administration narrowly recommended approving Belgian drugmaker UCB SA's rheumatoid arthritis drug for an additional indication.
Earnings vs. Estimates
Analyst Research Reports
UCB S.A.: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
Provider: Wright Reports
Provider: Thomson Reuters StreetEvents